Global Cancer Biomarkers Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027

MarketResearch.biz delivers in-depth insights on the global cancer biomarkers market in its upcoming report titled, “Global Cancer Biomarkers Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global cancer biomarkers market is estimated to register a CAGR of XX.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cancer biomarkers market report has been segmented on the basis of type, tumor type, technology, application, and region.

Cancer biomarkers are substances, used as indicators for biological state of tumors. Cancer biomarkers are used during diagnosis of cancer, especially during diagnostic and prognostic stages of cancer. Cancer biomarkers are used in three ways that help diagnose conditions as in the case of identifying early stage cancers, to forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment, and to predict how well a patient will respond to treatment.

Increasing incidence of cancer across the globe is a major factor driving growth of the global cancer biomarkers market. For instance, American Cancer Society stated that in 2017, there will be an estimated 1,688,780 new cancer cases diagnosed. In addition, growing awareness among individuals about importance of early diagnosis and advancements in cancer biomarkers are other factors expected to fuel growth of the global cancer biomarkers market over the forecast period.

However, high initial costs and low profit margins are major factors restraining growth of the global cancer biomarkers market. Additionally, lack of reimbursement policies and proper storage facilities for samples are other factors expected to hamper growth of the global cancer biomarkers market over the forecast period.

The market in North America is estimated to account for highest share in terms of revenue and is expected to maintain its dominance over the forecast period. This dominance can be attributed to increasing government initiatives for research & development of cancer biomarkers in countries in the region. The market in Asia Pacific is expected to register highest growth in the target market over the forecast period, owing to increasing prevalence of cancer in emerging economies such as China, India, etc. Moreover, market in Latin America and Middle East & Africa is projected to register moderate growth in the target market over the forecast period.

Global cancer biomarkers market segmentation:

By Type:

• Protein Biomarker
• Genetic Biomarker
• Others (cell, viral, and carbohydrate biomarkers)

By Tumor Type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Leukemia
• Others

By Technology:

• Omics
• Imaging
• Immunoassays
• Cytogenetics
• Bioinformatics

By Application:

• Drug discovery and Development
• Diagnostics
• Personalized medicine
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Roche Holding AG
• QIAGEN N.V.
• Illumina, Inc.
• Agilent Technologies, Inc.
• Abbott Laboratories
• Becton, Dickinson and Company
• Myriad Genetics, Inc.
• Sysmex Corporation